(-)-Chaetominine 是一种生物碱代谢物。 (-)-Chaetominine 对人白血病 K562 和结肠癌 SW1116 细胞系具有细胞毒性。 (-)-Chaetominine 通过抑制 K562/Adr 人白血病细胞中的 PI3K/Akt/Nrf2 信号通路降低 MRP1 介导的耐药性。
| Cas No. | 918659-56-0 |
| 别名 | (-)-Chaetominine |
| Canonical SMILES | O=C1N([C@H]2C)[C@]3([H])[C@](C4=CC=CC=C4N3C2=O)(O)C[C@H]1N5C=NC(C=CC=C6)=C6C5=O |
| 分子式 | C22H18N4O4 |
| 分子量 | 402.4 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | (-)-Chaetominine is a cytotoxic alkaloid originally isolated from Chaetomium sp. IFB-E015. It inhibits the growth of K562 leukemia and SW1116 colon cancer cells (IC50s = 20 and 28 nM, respectively). (-)-Chaetominine induces apoptosis of K562 cells via upregulation of the Bax/Bcl-2 ratio, decreasing mitochondrial membrane potential, inducing mitochondrial cytochrome C release, and activation of caspase-3 and caspase-9. It also decreases doxorubicin efflux mediated by multidrug resistance-associated protein 1 (MRP1) and restores sensitivity to doxorubicin in resistant K562 cells. |
m.cnreagent.com